Biodexa Pharmaceuticals (BDRX) Non-Current Deferred Tax Liability (2014 - 2025)

Biodexa Pharmaceuticals (BDRX) has 12 years of Non-Current Deferred Tax Liability data on file, last reported at $109.3 million in Q4 2025.

• For the quarter ending Q4 2025, Non-Current Deferred Tax Liability rose 6.79% year-over-year to $109.3 million; the trailing twelve-month figure through Dec 2025 stood at $109.3 million (up 6.79% YoY), and the FY2025 full-year result was $108.3 million, up 5.86% from the prior year.
• Non-Current Deferred Tax Liability climbed to $109.3 million in Q4 2025, from $102.3 million in the prior quarter.
• In the past five years, Non-Current Deferred Tax Liability ranged from a high of $109.3 million in Q4 2025 to a low of $83.4 million in Q4 2022.
• A 5-year average of $95.9 million and a median of $93.7 million in 2023 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability slipped 7.9% in 2022 and increased 12.35% in 2023, its largest moves.
• Tracing BDRX's Non-Current Deferred Tax Liability over 5 years: stood at $90.6 million in 2021, then declined by 7.9% to $83.4 million in 2022, then rose by 12.35% to $93.7 million in 2023, then gained by 9.18% to $102.3 million in 2024, then increased by 6.79% to $109.3 million in 2025.
• Business Quant data shows BDRX's Non-Current Deferred Tax Liability at $109.3 million in Q4 2025, $102.3 million in Q4 2024, and $93.7 million in Q4 2023.